TITLE

ETHYPHARM TO DEVELOP A FLASH VERSION OF AVENTIS' ALLEGRA

PUB. DATE
July 2002
SOURCE
Worldwide Biotech;Jul2002, Vol. 14 Issue 7, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a licensing agreement signed by Ethypharm with Aventis.
ACCESSION #
6939479

 

Related Articles

  • Bentley enters license deal.  // New Hampshire Business Review;02/25/2000, Vol. 22 Issue 5, p16 

    Informs that New Hampshire-based Bentley Pharmaceuticals has entered into a non-exclusive licensing agreement with Ethypharm to market the drug Diltiazem Hydrochloride Slow Release in Spain.

  • Ethypharm and Biovail enter into strategic alliance.  // Pharmaceutical Technology Europe;Jun2002, Vol. 14 Issue 6, p10 

    Announces the strategic alliance between Ethypharm and Biovail Corp. Establishment of licensing and product development program; Terms of the agreement; Development of drug delivery technologies by the companies.

  • Pharma: Other News To Note.  // BioWorld Today;3/ 7/2013, Vol. 24 Issue 44, p7 

    The article offers world news briefs related to the pharmaceutical industry which include the license distribution agreement signed by Grunenthal Group and EthyPharm SA, the $45 million settlement paid by Par Pharmaceutical Cos. Inc., and the agreement signed by Roche AG and BioLamina AB.

  • Aventis contributes $1 million to Red Cross.  // Pest Control;Feb2002, Vol. 70 Issue 2, p60 

    Reports the assistance of Aventis to the American Red Cross for the ongoing relief efforts following the terrorist attacks in Montvale, New Jersey.

  • Sanofi: Time not right to sell off beauty unit.  // WWD: Women's Wear Daily;9/8/1997, Vol. 174 Issue 48, p4 

    Focuses on pharmaceuticals and beauty products company, Sanofi's executive vice president for administration and finance, Jean-Paul Leon's issuance of a statement to clarify French business newspapers report that the company is planning to sell off its beauty division. Overview on Sanofi's...

  • Retork completes system upgrade at Aventis plant.  // Life Science Today;Jun2000, Vol. 1 Issue 3, p2 

    Focuses on the completion of the end control system project by Rotork Control and Safety at the Aventis research facility. Expansion of the pilot-scale control system; Importance of Good Automated Manufacturing Practice guidelines for the ownership of the project; Start-up problems of the project.

  • Aventis promotes improved Dr. Chart program, MyDocOline software. Arnold, Matthew // Medical Marketing & Media;May2003, Vol. 38 Issue 5, p30 

    Reports on Aventis Inc.'s upgrade of its MyDocOnline software suite with the launch of Practice Solutions software. Automation of billing and prescribing functions; Expansion of the Dr. Chart program; Efforts to improve patient compliance.

  • Aventis Streamlines R&D. Houlton, Sarah // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p21 

    Reports on Aventis' plan to reduce its research and development costs by spinning out a stake in one of its research units. Plans of the private equity house Warburg Pincus to invest in ProSkelia; Aventis' plan to spin off its gene therapy unit, Gencell.

  • Beauty sales at Sanofi decline 2%.  // WWD: Women's Wear Daily;4/14/1995, Vol. 169 Issue 72, p9 

    Reports on the decline in sales of Sanofi SA's beauty products and fragrances during the first quarter of 1995.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics